Seek Returns

BIO.B vs. SNY: Bio-Rad Laboratories vs. Sanofi Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while SNY is classified in Pharmaceuticals.

Bio-Rad Laboratories (BIO.B) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY)
Profile ItemBIO.BSNY
NameBio-Rad Laboratories, Inc. Class B Common StockSanofi ADR
Country/RegionUnited StatesFrance
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization10.49 billion USD112.71 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateSeptember 21, 1999July 1, 2002
Security TypeCommon StockADR

Price Performance

Cumulative Growth

BIO.B
SNY
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY)
MetricBIO.BSNY
Total Return (1Y)27.69%2.73%
Total Return (3Y, Annualized)9.13%6.89%
Total Return (5Y, Annualized)-12.33%3.16%

Risk Profile

Drawdown History

BIO.B
SNY
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Sanofi (SNY) trades around 3.29M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY)
MetricBIO.BSNY
Volatility (1Y, Annualized)30.96%23.60%
Beta (5Y)1.000.28
Max Drawdown (5Y)-70.74%-33.52%
Avg. Volume (3M)113.29M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and SNY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY)
MetricBIO.BSNY
Sharpe Ratio (1Y)0.74-0.07
Sortino Ratio (1Y)1.10-0.10

Profitability

ROE (TTM)

Bio-Rad Laboratories (BIO.B) at 14.27% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for BIO.B.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.72%

Max
109.18%
Q3
6.23%
SNY
5.72%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bio-Rad Laboratories (BIO.B) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.20%

Max
18.05%
SNY
8.20%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Sanofi (SNY) at 30.89% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.89%

Max
83.12%
SNY
30.89%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY)
MetricBIO.BSNY
ROE (TTM)14.27%5.72%
ROA (TTM)1.50%5.31%
Net Margin (TTM)39.45%8.20%
Operating Margin (TTM)9.46%30.89%
Gross Margin (TTM)52.19%73.68%

Growth

Revenue Growth

Both Bio-Rad Laboratories (BIO.B) at 0.65% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Sanofi (SNY) reports EPS growth of 39.43%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY)
MetricBIO.BSNY
Revenue Growth (YoY)0.65%5.49%
Revenue Growth (3Y CAGR)-2.68%4.82%
EPS Growth (YoY)--39.43%
EPS Growth (3Y CAGR)--6.02%

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 3.18 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.12

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
SNY
1.12
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Bio-Rad Laboratories (BIO.B) at 0.18 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.27

Max
1.42
Q3
0.65
SNY
0.27
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY)
MetricBIO.BSNY
Current Ratio (MRQ)3.181.12
Debt / Equity (MRQ)0.180.27
Net Debt / EBITDA-0.730.96

Dividends

Dividend Yield (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SNY
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Bio-Rad Laboratories (BIO.B) pays no dividend (payout 0.00%).

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

119.86%

SNY
119.86%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY)
MetricBIO.BSNY
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%119.86%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while Sanofi (SNY) at 23.40 is closer to its industry’s usual earnings multiple — a discount for BIO.B, though growth and earnings durability still matter.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.40

Max
85.34
Q3
43.46
Median
26.69
SNY
23.40
Q1
13.30
Min
0.07
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO.B) at 4.05 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.21

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
SNY
2.21
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Relative to net asset value, both Bio-Rad Laboratories (BIO.B) at 1.38 and Sanofi (SNY) at 1.38 look inexpensive, sitting in the lower P/B ratio quartile of their industries.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

SNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
SNY
1.38
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Sanofi (SNY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and Sanofi (SNY)
MetricBIO.BSNY
P/E Ratio (TTM)10.3623.40
P/S Ratio (TTM)4.052.21
P/B Ratio (MRQ)1.381.38
Free Cash Flow Yield (TTM)2.59%7.17%